1Department of Pharmacy, Intermountain Medical Center, Murray, Utah, USA.
2Department of Transplantation, Intermountain Medical Center, Murray, Utah, USA.
The FDA has recently approved a number of new direct acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virologic cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. In this review we summarize the available data regarding drug-drug interactions for direct acting antiviral agents. The interactions included are the most clinically relevant currently known. This review is intended to serve as a clinician's guide to understanding and managing these complex interactions.